GSK (NYSE:GSK) Lowered to “Buy” Rating by StockNews.com

GSK (NYSE:GSK) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Sunday.

A number of other equities research analysts have also recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

GSK opened at $33.47 on Friday. GSK has a 1 year low of $32.83 and a 1 year high of $45.92. The stock has a 50-day moving average price of $34.75 and a 200-day moving average price of $38.43. The firm has a market cap of $69.37 billion, a PE ratio of 21.73, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Hedge Funds Weigh In On GSK

Institutional investors have recently made changes to their positions in the business. DGS Capital Management LLC increased its position in GSK by 3.9% in the third quarter. DGS Capital Management LLC now owns 34,438 shares of the pharmaceutical company’s stock worth $1,408,000 after buying an additional 1,304 shares in the last quarter. Logan Capital Management Inc. grew its stake in shares of GSK by 3.8% during the 3rd quarter. Logan Capital Management Inc. now owns 83,923 shares of the pharmaceutical company’s stock valued at $3,431,000 after acquiring an additional 3,083 shares during the period. Franklin Resources Inc. increased its holdings in GSK by 8.6% in the 3rd quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company’s stock worth $9,052,000 after acquiring an additional 18,539 shares in the last quarter. Optimist Retirement Group LLC increased its stake in shares of GSK by 3.7% in the third quarter. Optimist Retirement Group LLC now owns 49,554 shares of the pharmaceutical company’s stock worth $2,026,000 after purchasing an additional 1,790 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of GSK during the 3rd quarter valued at $787,000. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.